Immunomodulatory function of the tumor suppressor p53 in host immune response and the tumor microenvironment

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

The tumor suppressor p53 is the most frequently mutated gene in human cancers. Most of the mutations are missense leading to loss of p53 function in inducing apoptosis and senescence. In addition to these autonomous effects of p53 inactivation/dysfunction on tumorigenesis,compelling evidence suggests that p53 mutation/inactivation also leads to gain-of-function or activation of non-autonomous pathways,which either directly or indirectly promote tumorigenesis. Experimental and clinical results suggest that p53 dysfunction fuels pro-tumor inflammation and serves as an immunological gain-of-function driver of tumorigenesis via skewing immune landscape of the tumor microenvironment (TME). It is now increasingly appreciated that p53 dysfunction in various cellular compartments of the TME leads to immunosuppression and immune evasion. Although our understanding of the cellular and molecular processes that link p53 activity to host immune regulation is still incomplete,it is clear that activating/reactivating the p53 pathway in the TME also represents a compelling immunological strategy to reverse immunosuppression and enhance antitumor immunity. Here,we review our current understanding of the potential cellular and molecular mechanisms by which p53 participates in immune regulation and discuss how targeting the p53 pathway can be exploited to alter the immunological landscape of tumors for maximizing therapeutic outcome.

Original languageEnglish (US)
Article number1942
JournalInternational journal of molecular sciences
Volume17
Issue number11
DOIs
StatePublished - Nov 19 2016

Fingerprint

suppressors
Tumor Microenvironment
Tumors
tumors
Carcinogenesis
immunosuppression
Immunosuppression
Neoplasms
mutations
Immune Evasion
deactivation
Missense Mutation
Immunity
immunity
apoptosis
Cell death
compartments
Apoptosis
Inflammation
genes

Keywords

  • Adaptive antitumor immunity
  • Immune suppression
  • Immunotherapy
  • Inflammation
  • Innate immunity
  • P53 inactivation
  • Tumor microenvironment
  • Tumor suppressor p53

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

@article{9815c9052d9c438ca04b94b58963b30b,
title = "Immunomodulatory function of the tumor suppressor p53 in host immune response and the tumor microenvironment",
abstract = "The tumor suppressor p53 is the most frequently mutated gene in human cancers. Most of the mutations are missense leading to loss of p53 function in inducing apoptosis and senescence. In addition to these autonomous effects of p53 inactivation/dysfunction on tumorigenesis,compelling evidence suggests that p53 mutation/inactivation also leads to gain-of-function or activation of non-autonomous pathways,which either directly or indirectly promote tumorigenesis. Experimental and clinical results suggest that p53 dysfunction fuels pro-tumor inflammation and serves as an immunological gain-of-function driver of tumorigenesis via skewing immune landscape of the tumor microenvironment (TME). It is now increasingly appreciated that p53 dysfunction in various cellular compartments of the TME leads to immunosuppression and immune evasion. Although our understanding of the cellular and molecular processes that link p53 activity to host immune regulation is still incomplete,it is clear that activating/reactivating the p53 pathway in the TME also represents a compelling immunological strategy to reverse immunosuppression and enhance antitumor immunity. Here,we review our current understanding of the potential cellular and molecular mechanisms by which p53 participates in immune regulation and discuss how targeting the p53 pathway can be exploited to alter the immunological landscape of tumors for maximizing therapeutic outcome.",
keywords = "Adaptive antitumor immunity, Immune suppression, Immunotherapy, Inflammation, Innate immunity, P53 inactivation, Tumor microenvironment, Tumor suppressor p53",
author = "Yan Cui and Gang Guo",
year = "2016",
month = "11",
day = "19",
doi = "10.3390/ijms17111942",
language = "English (US)",
volume = "17",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

TY - JOUR

T1 - Immunomodulatory function of the tumor suppressor p53 in host immune response and the tumor microenvironment

AU - Cui, Yan

AU - Guo, Gang

PY - 2016/11/19

Y1 - 2016/11/19

N2 - The tumor suppressor p53 is the most frequently mutated gene in human cancers. Most of the mutations are missense leading to loss of p53 function in inducing apoptosis and senescence. In addition to these autonomous effects of p53 inactivation/dysfunction on tumorigenesis,compelling evidence suggests that p53 mutation/inactivation also leads to gain-of-function or activation of non-autonomous pathways,which either directly or indirectly promote tumorigenesis. Experimental and clinical results suggest that p53 dysfunction fuels pro-tumor inflammation and serves as an immunological gain-of-function driver of tumorigenesis via skewing immune landscape of the tumor microenvironment (TME). It is now increasingly appreciated that p53 dysfunction in various cellular compartments of the TME leads to immunosuppression and immune evasion. Although our understanding of the cellular and molecular processes that link p53 activity to host immune regulation is still incomplete,it is clear that activating/reactivating the p53 pathway in the TME also represents a compelling immunological strategy to reverse immunosuppression and enhance antitumor immunity. Here,we review our current understanding of the potential cellular and molecular mechanisms by which p53 participates in immune regulation and discuss how targeting the p53 pathway can be exploited to alter the immunological landscape of tumors for maximizing therapeutic outcome.

AB - The tumor suppressor p53 is the most frequently mutated gene in human cancers. Most of the mutations are missense leading to loss of p53 function in inducing apoptosis and senescence. In addition to these autonomous effects of p53 inactivation/dysfunction on tumorigenesis,compelling evidence suggests that p53 mutation/inactivation also leads to gain-of-function or activation of non-autonomous pathways,which either directly or indirectly promote tumorigenesis. Experimental and clinical results suggest that p53 dysfunction fuels pro-tumor inflammation and serves as an immunological gain-of-function driver of tumorigenesis via skewing immune landscape of the tumor microenvironment (TME). It is now increasingly appreciated that p53 dysfunction in various cellular compartments of the TME leads to immunosuppression and immune evasion. Although our understanding of the cellular and molecular processes that link p53 activity to host immune regulation is still incomplete,it is clear that activating/reactivating the p53 pathway in the TME also represents a compelling immunological strategy to reverse immunosuppression and enhance antitumor immunity. Here,we review our current understanding of the potential cellular and molecular mechanisms by which p53 participates in immune regulation and discuss how targeting the p53 pathway can be exploited to alter the immunological landscape of tumors for maximizing therapeutic outcome.

KW - Adaptive antitumor immunity

KW - Immune suppression

KW - Immunotherapy

KW - Inflammation

KW - Innate immunity

KW - P53 inactivation

KW - Tumor microenvironment

KW - Tumor suppressor p53

UR - http://www.scopus.com/inward/record.url?scp=84996565480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996565480&partnerID=8YFLogxK

U2 - 10.3390/ijms17111942

DO - 10.3390/ijms17111942

M3 - Review article

C2 - 27869779

AN - SCOPUS:84996565480

VL - 17

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 11

M1 - 1942

ER -